Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L19IL2/L19TNF in Locally Advanced Basal Cell Carcinoma
NCT07227870Phase 2Recruiting
- Sponsor
- Philogen
- Start
- Sep 2026
- Primary completion
- Feb 2031
- Modality
- Antibody Fragments, Immunomodulatory ADCs, Cytokines & Interferons
- Countries
- 5
01
Overview
A Phase 2 trial of darleukin, onfekafusp alfa in basal cell carcinoma (BCC), sponsored by Philogen. Started Sep 2026; status: recruiting.
02
Drugs
darleukinonfekafusp alfa
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT07227870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07227870.